Abstract
Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 260-279 |
| Number of pages | 20 |
| Journal | Integrative Cancer Therapies |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- chemotherapy
- Chinese herbal medicine
- lung cancer
- marginal structural models
- propensity score
- radiotherapy
- survival
- vitamins
ASJC Scopus subject areas
- Complementary and alternative medicine
- Oncology
Cite this
Lung cancer survival with herbal medicine and vitamins in a whole-systems approach : Ten-year follow-up data analyzed with marginal structural models and propensity score methods. / McCulloch, Michael; Broffman, Michael; Van Der Laan, Mark; Hubbard, Alan; Kushi, Lawrence; Kramer, Alan; Gao, Jin; Colford, John M.
In: Integrative Cancer Therapies, Vol. 10, No. 3, 09.2011, p. 260-279.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lung cancer survival with herbal medicine and vitamins in a whole-systems approach
T2 - Ten-year follow-up data analyzed with marginal structural models and propensity score methods
AU - McCulloch, Michael
AU - Broffman, Michael
AU - Van Der Laan, Mark
AU - Hubbard, Alan
AU - Kushi, Lawrence
AU - Kramer, Alan
AU - Gao, Jin
AU - Colford, John M.
PY - 2011/9
Y1 - 2011/9
N2 - Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.
AB - Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.
KW - chemotherapy
KW - Chinese herbal medicine
KW - lung cancer
KW - marginal structural models
KW - propensity score
KW - radiotherapy
KW - survival
KW - vitamins
UR - http://www.scopus.com/inward/record.url?scp=84855363742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855363742&partnerID=8YFLogxK
U2 - 10.1177/1534735411406439
DO - 10.1177/1534735411406439
M3 - Article
C2 - 21824893
AN - SCOPUS:84855363742
VL - 10
SP - 260
EP - 279
JO - Integrative Cancer Therapies
JF - Integrative Cancer Therapies
SN - 1534-7354
IS - 3
ER -